CHADD is part of a social movement that seeks to shape the conversation on how society treats, accommodates, and views people affected by ADHD. Our movement is made up of countless people affected by ADHD, their families, teachers, friends, and leaders in the fields of ADHD research, education, and mental health. We realize the most effective way to accomplish our goals is through sustained and strategic outreach to policymakers on the state and federal levels.

We are making a difference for for families and adults affected ADHD. And we need your help! We want you to be equipped with information to make a difference in your own life, whether that means dealing with issues in the classroom, the boardroom, or your living room.


CHADD’s Statement at the Public Meeting on Patient-Focused Drug Development for Stimulant Use Disorder

October 8, 2020

Presentation to the Joint Meeting of the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee of the US Food and Drug Administration Public Meeting on Patient-Focused Drug Development for Stimulant Use Disorder Presented by Robert Cattoi, CHADD Chief Executive Officer Children and Adults with Attention-Deficit/Hyperactivity Disorder (CHADD) appreciates the opportunity…

UPDATE: CARES Act And Protecting Educational Rights of Students With ADHD

April 29, 2020

CHADD is pleased to report that Secretary of Education Betsy DeVos will not seek changes to the central tenets of the Individuals with Disabilities Education Act (IDEA) in response to the novel coronavirus pandemic. In her report, the Secretary is “not requesting waiver authority for any of the core tenets of the IDEA or Section…

CARES Act And Protecting Educational Rights of Students With ADHD

April 21, 2020

Read the update to this post. Dear Parents, The Coronavirus Aid, Relief, and Economic Security (CARES) Act, PL 116-136, directs Secretary of Education Betsy DeVos to report back to Congress no later than April 26, 2020, on any waivers needed under the Individuals with Disabilities Education Act (IDEA) and the Rehabilitation Act of 1973 (Section…

Q&A: Providing Services to Children with ADHD & Disabilities During the COVID-19 Outbreak

April 8, 2020

The CHADD Public Policy Committee is sharing the document Questions and Answers on Providing Services to Children with Disabilities during the Coronavirus Disease 2019 Outbreak. This document addresses questions on IDEA and Section 504 educational plans, along with meeting the needs of children with disabilities who may also be affected by COVID-19. The Centers for…

CHADD Responds to FDA Request for Comments on ADHD Medications

November 21, 2019

The US Food and Drug Administration recently asked for comments on making stimulant medications more difficult to abuse and how those changes could affect the millions of people who include medication in their ADHD treatment plans. The Federal Register notice states that stimulant medications can be open to abuse but that reformulating them can potentially…

Charter Schools: Discipline and Implications for Students with ADHD

March 6, 2019

At eight years old, Michael was diagnosed with ADHD. The traditional city school he attended declined to evaluate him to determine eligibility for special education and related services because his grades were above average. Instead, the school provided Michael with minimal accommodations through a 504 plan. As the years progressed, Michael’s grades began to decline,…

New Research Suggests Untreated ADHD Reduces Life Expectancy

January 8, 2019

CHADD and Russell A. Barkley, Ph.D., Partner Announce New Findings   Lanham, Md. (Jan. 8, 2019)— The message is clear. Treatment for attention-deficit/hyperactivity disorder (ADHD), along with the related health risks it poses, has the possibility of adding an average of nine to 13 years to the lifespan of children and adults diagnosed with ADHD.…

CHADD Position Statement on Controlled Substances Measures

July 24, 2017

CHADD has become aware of state and local policies, including legislation and regulations, intended to address the misuse of opioids, but which may have unintended consequences for children and adults prescribed FDA-approved medications to treat attention deficit hyperactivity disorder (ADHD). Read the full statement.

CHADD’s Position on Patient Access to ADHD Medications

May 15, 2017

Medication Access Principles: CHADD ascribes to the following principles regarding access to medications indicated to treat attention deficit / hyperactivity disorder (ADHD). Medication is recognized by the scientific community as a primary treatment to effectively reduce the core symptoms of ADHD.[1] Given the stigma associated with ADHD and common misconceptions about treating the disorder, individuals…

American Health Care Act

May 15, 2017

The House of Representatives had been preparing to vote on the American Health Care Act (AHCA), which would repeal significant portions of the Affordable Care Act (ACA or “Obamacare”) and replace them with alternative coverage policies. At this time, the House is not moving forward with a vote on the AHCA. Read our full report.